Hangzhou Tigermed Consulting Co., Ltd Stock
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
57.05 CNY | +0.25% | +5.79% | +3.78% |
Apr. 25 | Hangzhou Tigermed Consulting’s Profit Down 59% in Q1 | MT |
Apr. 25 | Hangzhou Tigermed Consulting Co., Ltd Reports Earnings Results for the First Quarter Ended March 30, 2024 | CI |
Sales 2024 * | 7.94B 1.1B | Sales 2025 * | 9.8B 1.35B | Capitalization | 45.98B 6.35B |
---|---|---|---|---|---|
Net income 2024 * | 2.05B 283M | Net income 2025 * | 2.51B 346M | EV / Sales 2024 * | 4.93 x |
Net cash position 2024 * | 6B 828M | Net cash position 2025 * | 8.35B 1.15B | EV / Sales 2025 * | 3.84 x |
P/E ratio 2024 * |
24.2
x | P/E ratio 2025 * |
19.8
x | Employees | - |
Yield 2024 * |
0.88% | Yield 2025 * |
1.1% | Free-Float | 69.68% |
1 day | +0.25% | ||
1 week | +5.79% | ||
Current month | +5.79% | ||
1 month | -7.54% | ||
3 months | +38.54% | ||
6 months | +1.01% | ||
Current year | +3.78% |
Managers | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Hao Wu
PSD | President | 56 | 19-12-31 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Xiao Chun Cao
CEO | Chief Executive Officer | 55 | 04-12-31 |
Bing Hui Zhang
CHM | Chairman | 61 | 20-04-27 |
Xiao Ping Ye
CHM | Chairman | 61 | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 57.05 | +0.25% | 9,795,335 |
24-06-06 | 56.91 | +2.87% | 9,368,382 |
24-06-05 | 55.32 | -0.32% | 5,851,840 |
24-06-04 | 55.5 | +3.54% | 9,540,997 |
24-06-03 | 53.6 | -0.61% | 8,610,114 |
End-of-day quote Shenzhen S.E., June 06, 2024
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.78% | 6.35B | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- 300347 Stock